The vaccine against the coronavirus being developed at the Oxford University in the United Kingdom is likely to arrive in India by November and will be worth around Rs 1,000, NDTV reported, citing the Indian company collaborating with the British experts. The Serum Institute of India on Monday said it will apply for a licence to start clinical trials of the coronavirus vaccine developed at Oxford University. The Pune firm is the world’s largest vaccine maker in terms of the number of doses produced and sold globally. It has partnered with biopharmaceutical company AstraZeneca to mass produce the Oxford vaccine. India is among the largest manufacturer of generic drugs and vaccines in the world.
“We are confident on going on to the Phase 3 trials in India in August and we forecast that it will take probably two to two-and-half months to complete,” Adar Poonawalla, chief executive officer of Serum Institute of India said. “By November, we hope to launch the vaccine if the trials are positive and if the Drug Controller of India blesses it and says it is safe and effective.”
The Serum Institute expects to vaccinate everyone in India in two years. Half of the stock of the Covishield vaccine manufactured at the institute will be exported, which implies out of around 60 million vials made every month, India will receive 30 million.